Michael Doster |

Doster Nations Ullom & Boyle, LLC

Michael Doster | Doster Nations Ullom & Boyle, LLC

Rating:

Firm Summary

Michael Doster is a member of the firm’s business, real estate, and estate planning practice group. Over the course of his career, he has been a member of and had leadership roles in many civic, service, trade, and charitable organizations. Currently, he limits his active involvement to organizations which promote community and economic development.

AREAS OF PRACTICE

• General business law (including formation, governance, operations, transactions, mergers and acquisitions)
• Real estate (including transactions, land use and development)
• Estate planning (including wills, trusts, gifts, succession planning, estate and trust administration)

EDUCATION

• Washington University School of Law, Juris Doctorate, 1973
• Case Western Reserve University, Bachelor of Arts in Economics, 1970

ADMITTED TO PRACTICE

• Missouri, 1973

AWARDS AND DISTINCTIONS

• AV® Preeminent™ Martindale-Hubbell® Peer Review RatingsSM
• 1999 Chamber of Commerce Businessperson of the Year
• Excellence in Economic Development from Progress 64 West

RELEVANT REPRESENTATION

• Represented one of the largest privately owned retail developers in the country in planning and zoning and development of shopping center properties
• Represented a Chicago-based high-end shopping center developer in the development of a lifestyle center that was the first of its kind in the St. Louis metropolitan area
• Represented residential developers (including local and national single family, multi-family, and senior living developers)
• Represented local, regional, national and international service and manufacturing businesses
• Developed new municipal planning and zoning ordinances to provide for the development of a large-scale mixed-use development
• Led a team of attorneys in a transaction that resulted in the sale of a majority interest in a highly successful international marketing firm to a hedge fund
• Led a team of attorneys in the sale of related biotechnology companies to an international public pharmaceutical company